BioAlberta supports the call for a new and stronger biomanufacturing strategy for Canada
A letter to:
The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry
The COVID-19 pandemic has revealed serious deficiencies in Canada’s domestic supply chain of vital medicines required to keep our citizens safe and our economy functioning. The resulting impacts of vaccine nationalism on Canada’s ability to procure critical vaccines from its allies highlights the importance of a strong domestic biomanufacturing industry as a matter of both economic and national security. In parallel, the COVID-19 pandemic has also demonstrated the strength of Canada’s R&D institutions which have made critical contributions to the global innovation response. Outside of crisis periods, soaring drug prices and more advanced biologic therapies coming on to the market are placing enormous cost pressure on healthcare payor systems. Domestic multi-product manufacturing capacity to cost-effectively and sustainably supply provinces with complex medical therapies should be in the best interest of the Canadian Government’s investment considerations.
A public consultation was recently launched by Innovation, Science, and Economic Development Canada (ISED). In response to the consultation request, Alberta stakeholders in the life sciences value chain have collectively synthesized a response. We believe that Alberta is uniquely positioned to play a key role in enhancing domestic biomanufacturing capacity and recapture Canada’s leadership position on the global stage. Read the full response letter here.